We think that T-DM1, which was detected with a low incidence of skin toxicity in studies, may form telangiectatic lesions due to vascular dilatation through emtansine, and therefore care should be taken in the treatment of T-DM1.Īdo-trastuzumab emtansine (T-DM1) Breast cancer human epidermal growth factor receptor 2 (HER2). In these lesions, which did not require any treatment, no regression was observed during T-DM1 treatment. While no side effects were observed during the use of T-DM1 for HER2 positive disease, nose bleeding and spider telangiectasia on the skin developed in the 9th month of the treatment.
Management of symptomatic adverse reactions may require temporary. Patients receiving Herceptin and chemo experienced more neuropathy and. In our case, we reported our patient who developed mucosal and cutaneous telangiectasia after T-DM1 treatment and who had a complete response in metastases after skin lesions. covalently linked to DM1, a microtubule inhibitor, via the stable thioether linker MCC. Fatigue was similar for both groups, with around a quarter of patients reporting fatigue. The most common side effects are fatigue, diarrhea, anemia, and it is generally a safe and tolerable agent. Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of HER2 target monoclonal antibody trastuzumab and microtubule inhibitor emtansine. is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. DM1, the cytotoxic component of KADCYLA, may cause serious adverse reactions in breastfed infants based on its mechanism of action. Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate. Human epidermal growth factor receptor 2 (HER2) positivity rate is 20% and generally has a poor prognosis. There is no information regarding the presence of ado-trastuzumab emtansine in human milk, the effects on the breastfed infant, or the effects on milk production. Breast cancer is the most common cancer in women.